Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Turmeric and blue light may heal blisters in rare skin disease

NCT ID NCT07596927

Symptom relief Sponsor: Universidade Ceuma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests whether a gel made from curcumin (the active part of turmeric) combined with blue LED light can heal painful mouth blisters in people with epidermolysis bullosa, a rare condition that makes skin and mucous membranes extremely fragile. Twenty participants will receive the treatment for three days, and researchers will track how well the blisters heal and whether quality of life improves. The study also looks for biomarkers in saliva that could help diagnose or monitor the disease without needing a biopsy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
curcumin gel with blue LED light
What this could lead to
If it works, this could offer a simple, non-invasive way to heal painful mouth blisters and improve daily life for people with epidermolysis bullosa.
What could go wrong
This is a very small study (20 people) with no placebo group, so results may not apply widely. The treatment is short-term and only targets oral lesions, not the underlying disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

20 people

The number who actually took part.

Started

Jan 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children, adolescents, and adults diagnosed with epidermolysis bullosa (EB), regardless of subtype * Participants who are able to receive oral feeding Individuals receiving care at the NINAR Reference Center or residing in São Luís or the state of Maranhão * Participants (or legal guardians) who provide written informed consent; assent obtained from minors when applicable * Ability to undergo oral clinical examination and photodynamic therapy procedures Exclusion Criteria: * Individuals with epidermolysis bullosa who present physical and/or mental conditions that prevent cooperation with oral examination or treatment procedures * Participants unable to comply with study procedures, including clinical evaluation, saliva collection, or photodynamic therapy * Individuals with conditions that contraindicate the application of photodynamic therapy in the oral cavity (e.g., severe intolerance to light exposure or topical agents) * Participants currently undergoing other experimental treatments that may interfere with the study outcomes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epidermolysis bullosa (EB) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired epidermolysis bullosa epidermolysis bullosa epidermolysis bullosa dystrophica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epidermolysis bullosa (EB) Epidermolysis bullosa acquisita Epidermolysis bullosa dystrophica

Contacts and locations

Locations

  • Rua Perdizes, Quadra 35, n. 27/805, Jardim Renascença

    São Luís, Maranhão, 65075340, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.